Información del artículo
El síndrome metabólico (SM) define una enfermedad centrada en la resistencia insulínica (RI) y en la que se encuentra implicado el tejido adiposo disfuncionante. Las alteraciones del metabolismo glucolipídico tienen un componente genético y son favorecidas por la inactividad física y la obesidad.
En la actualidad, la obesidad es un problema de salud con una alta prevalencia y múltiples repercusiones orgánicas. El aumento del sobrepeso infantil es especialmente llamativo. El papel de la obesidad como factor de riesgo independiente para la enfermedad cardiovascular es controvertido, ya que, en parte, se explica por factores de riesgo clásicos asociados a ella.
La dislipemia característica del SM, la hipertrigliceridemia con cifras bajas de colesterol unido a lipoproteínas de alta densidad, es consecuencia de la hiperinsulinemia en el metabolismo de las lipoproteínas. Aunque la elevación de las lipoproteínas de baja densidad no es característica del SM, la presencia de cambios en su composición sí lo es y da lugar a las denominadas SDLDL, más pequeñas, densas y aterogénicas.
Palabras clave:
Obesidad
Dislipemia
Síndrome metabólico
Insulin resistance plays a central role in the pathophysiology of the metabolic syndrome, though adipose tissue abnormalities may also be involved. Physical inactivity and excessive weight can lead to impaired lipid and glucose metabolism in patients with a genetic predisposition to insulin resistance. Today, obesity is a serious public health problem, in children as well as adults. Whether or not being overweight is an independent risk factor for cardiovascular disease is controversial, since it is associated with more traditional cardiovascular risk factors. The dyslipidemia typical of the metabolic syndrome, which is characterized by a high triglyceride level with a low high-density lipoprotein cholesterol level, results from the effect of hyperinsulinemia on lipoprotein metabolism. However, an elevated low-density lipoprotein (LDL) cholesterol level is not characteristic of the syndrome. Nevertheless, structural changes occur in LDL cholesterol particles, which become smaller, more dense and more atherogenic.
Key words:
Obesity
Dyslipidemia
Metabolic syndrome
El Texto completo está disponible en PDF
Bibliografía
[1.]
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
[2.]
N. Sattar, A. Gaw, O. Scherbakova, I. Ford, D.S. O’Reilly, S.M. Haffner, et al.
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
Circulation, 108 (2003), pp. 414-419
[3.]
Zachary T, Bloomgarden MD. Highlights From The First World Congress on the Insulin Resistance Syndrome. Medscape Diabetes & Endocrinology 2004;6. Disponible en: http://www.medsca-pe.com/viewarticle/467200
[4.]
P. Zimmet, E.J. Boyko, G.R. Collier, M. De Courten.
Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players.
Ann NY Acad Sci, 892 (1999), pp. 25-44
[5.]
J.P. Després.
The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients’ risk.
Obes Res, 6 (1998), pp. 8-17
[6.]
L.C. Groop.
Insulin resistance: the fundamental trigger of type 2 diabetes.
Diabetes Obes Metab, 1 (1999), pp. 1-7
[7.]
A.T. Kraja, S.C. Hunt, J.S. Pankow, R.H. Myers, G. Heiss, C.E. Lewis, et al.
An evaluation of the metabolic syndrome in the HyperGEN study.
Nutr Metabol, 2 (2005), pp. 2
[8.]
J.K. Olijhoek, F.M. Martens, J.D. Banga, F.L. Visseren.
The metabolic syndrome: a cluster of vascular risk factors.
Ned Tijdschr Geneeskd, 149 (2005), pp. 2162
[9.]
R.J. Kuczmarski, D.M. Flegal, S.M. Campbell, C.L. Johanson.
Incresing prevalencie of overweight amon US. Adults: the National Health and Nutrition Examination Surveys. 1960 to 1991.
JAMA, 272 (1994), pp. 205-211
[10.]
J. Aranceta, M. Foz, B. Gil, E. Jover, T. Mantilla, J. Millán, et al.
Documento de consenso: obesidad y riesgo cardiovascular.
Clin Invest Arterioscl, 15 (2003), pp. 196-233
[11.]
S.C. Smith Jr, L.T. Clark, R.S. Cooper, S.R. Daniels, S.K. Kumanyika, E. Ofili, American Heart Association Obesity, Metabolic Syndrome, and Hypertension Writing Group, et al.
Discovering the Full Spectrum of Cardiovascular Disease. Minority Health Summit 2003.Report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group.
Circulation, 111 (2005), pp. e134-e139
[12.]
S.R. Daniels, D.K. Arnett, R.H. Eckel, S.S. Gidding, L.L. Hayman, S. Kumanyika, et al.
Overweight in children and adolescents. Pathophysiology, consequences, prevention, and treatment.
Circulation, 111 (2005), pp. 1999-2012
[13.]
G. Lena Vega.
Obesity, the metabolic syndrome and cardiovascular disease.
Am Heart J, 142 (2001), pp. 1108
[14.]
J.M. Kearney, M.J. Kearney, S. McElhone, M.J. Gibney.
Methods used to conduct the pan-European surbey on consumer attitudes to physical activity, body weight and health.
Public Health Nutr, 2 (1999), pp. 125-133
[15.]
M.D. Grundy.
Obesity, metabolic syndrome, and coronary atherosclerosis.
Circulation, 105 (2002), pp. 2696-2698
[16.]
R. Weiss, J. Dziura, T.S. Burgert, W.V. Tamborlane.
Obesity and the metabolic syndrome in children and adolescents.
N Engl J Med, 350 (2004), pp. 2362-2367
[17.]
S. Klein, L.E. Burke, G.A. Bray.
Clinical implications of obesity with specific focus on cardiovascular disease.
Circulation, 110 (2004), pp. 2952-2967
[18.]
G. Marchesini, N. Melchionda, G. Apolone, M. Cuzzolaro, E. Mannucci, F. Corica, QUOVADIS Study Group, et al.
Obesity and metabolic syndrome in treatment seeking obese patients.
Metabolism, 53 (2004), pp. 435-440
[19.]
S. Klein, L.E. Burke, G.A. Bray, S. Balir, D.B. Allison, X. Pi-Sunyer, et al.
Clinical implications of obesity with special focus on cardiovascular disease.
Circulation, 110 (2004), pp. 2952-2967
[20.]
G.A. Bray.
Medical consequences of obesity.
J Clin Endocrinol Metab, 89 (2004), pp. 2583-2589
[21.]
H.M. Lakka, T.A. Lakka, J. Tuomilehto, J.T. Salonen.
Abdominal obesity is associated with increased risk of acute coronary events in men.
Eur Heart J, 23 (2002), pp. 706-713
[22.]
L.J. Aronne.
Classification of obesity and assessment of obesityrelated health risks.
Obes Res, 10 (2002), pp. 105-115
[23.]
M. Galinier, A. Pathak, J. Roncalli.
Obesité et insufissance cardiaque.
Arch Mal Coeur, 98 (2005), pp. 39-45
[24.]
I.D. Caterson, V. Hubbard, G.A. Bray, R. Grunstein, B.C. Hansen, Y. Hong, et al.
American Heart Association. Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke. Group III: worldwide comorbidities of obesity.
Circulation, 110 (2004), pp. e476-e483
[25.]
J.W. Anderson, E.C. Konz.
Obesity and Disease Management: Effects of weight loss on comorbid conditions.
Obesity Research, 9 (2001), pp. 326-334
[26.]
A.M. Kanaya, E. Vittinghoff, M.G. Shlipak, H.E. Resnick, M. Visser, D.E. Barrett-Connor.
Association of total and central obesity with mortality in postmenopausal women with coronary heart disease.
Am J Epidemiol, 158 (2003), pp. 1161-1170
[27.]
S.D. De Ferranti, K. Gauvreau, D.S. Ludwig, E.J. Neufeld, J.W. Newburger, N. Rifai.
Prevalence of the metabolic syndrome in american adolescents. Findings from the third national health and nutrition examination survey.
Circulation, 110 (2004), pp. 2494-2497
[28.]
S.R. Daniels, D.K. Arnett, R.H. Eckel.
Overweight in children and adolescents pathophysiology, consequences, prevention, and treatment.
Circulation, 111 (2005), pp. 1999-2012
[29.]
C.L. Williams, L. Hayman.
Cardiovascular health in childhood. A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association.
Circulation, 106 (2002), pp. 143-160
[30.]
J. Steinberger, S.R. Daniels.
Obesity, insulin resistance, diabetes, and cardiovascular risk in children.
Circulation, 107 (2003), pp. 1448-1453
[31.]
E.M. Urbina, S.S. Gidding, W. Bao, A. Elkasabany, G.S. Berenson.
Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: the Bogalusa Heart Study.
Am Heart J, 138 (1999), pp. 122-127
[32.]
H.E. Bays, E.A. Stein.
Pharmacotherapy for dyslipidemia: current therapies and future agents.
Expert Opin Pharmacother, 4 (2003), pp. 1901-1938
[33.]
H.B. Brewer Jr, S. Santamarina-Fojo.
Clinical significance of highdensity lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate–binding cassette protein A1 transporter.
Am J Cardiol, 92 (2003), pp. K10-K16
[34.]
N. Mekki, M.A. Christofilis, M. Charbonnier, C. Atlan-Gepner, C. Defoort, C. Juhel, et al.
Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women.
J Clin Endocrinol Metab, 84 (1999), pp. 184-191
[35.]
B. Lamarche, S. Desroches.
Metabolic syndrome and effects of conjugated linoleic acid in obesity and lipoprotein disorders: the Québec experience.
Am J Clin Nutr, 79 (2004), pp. 1149-1152
[36.]
E. Luengo.
Las dislipemias como factor de riesgo. Definición, clasificación y diagnóstico.
Manual de cardiología preventiva, pp. 57-71
[37.]
P. Julien, M-C. Vohl, D. Gaudet, C. Gagné, G. Lévesque, J.P. Després, et al.
Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency.
Diabetes, 46 (1997), pp. 2063-2068
[38.]
M. Carr, J.D. Brunzell.
Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.
J Clin Endocrinol Metab, 89 (2004), pp. 2601-2607
[39.]
P.W.F. Wilson, R.B. D’Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kannel.
Prediction of coronary heart disease using risk factor categories.
Circulation, 97 (1998), pp. 1837-1847
[40.]
H. Bays, N. Abate, M. Chandalia.
Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
Future Cardiol, 1 (2005), pp. 39-59
[41.]
B. Hansel, P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M.J. Chapman, et al.
Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.
J Clin Endocrinol Metab, 89 (2004), pp. 4963-4971
[42.]
A. Cordero, A. Grima, J.A. Casasnovas, M. Laclaustra, E. Luengo, I.J. Ferreira, et al.
Registro MESYAS: prevalencia de síndrome metabólico en población laboral.
Congreso de las Enfermedades Cardiovasculares,
[43.]
E.S. Ford, W.H. Giles, W.H. Dietz.
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.
JAMA, 287 (2002), pp. 356-359
[44.]
A. Tchernof, B. Lamarche, D. Prud’homme.
The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.
Diab Care, 19 (1996), pp. 629-637
[45.]
J.D. Brunzell, A.F. Ayyobi.
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Am J Med, 115 (2003), pp. S24-S28
[46.]
T. Bjornheden, A. Babyi, G. Bondjers, O. Wiklund.
Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system.
Atherosclerosis, 123 (1996), pp. 43-56
[47.]
D.L. Tribble, M. Rizzo, A. Chait, D.M. Lewis, P.J. Blanche, R.M. Krauss.
Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins.
Am J Med, 110 (2001), pp. 103-110
[48.]
N. Sattar, K. Williams, A.D. Sniderman, R. D’Agostino, S.M. Haffner.
Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study.
Circulation, 110 (2004), pp. 2697-2703
[49.]
P.J. Talmud, E. Hawe, G.J. Miller.
Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men.
Arterioscler Thromb Vasc Biol, 22 (2002), pp. 1918-1923
[50.]
A.L. Avins, J.M. Neuhaus.
Do triglycerides provide meaningful information about heart disease risk?.
Arch Intern Med, 160 (2000), pp. 1937-1944
[51.]
A. Onat, G. Hergenc, V. Sansoy, M. Fobker, K. Ceyhan, S. Toprak, et al.
Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
Atherosclerosis, 168 (2003), pp. 81-89
Copyright © 2005. Sociedad Española de Cardiología
